Imugene granted patent in Japan!

https://www.imugene.com/announcements

$IUGNF/$IMU(ASX)CANCER treatment/not ur avg penny play

We have received ethics approval from the external independent Human Research Ethics Committee (HREC) in Australia and Independent Review Boards (IRB'S) in the USA, in addition to the coveted US FDA Investigational New Drug (IND) approval to begin Phase 1 clinical trails of our immunotherapy drug, PD1-Vaxx. Read the entire newsletter with links on site.

From the Chairman Paul Hopper in Dec newsletter: "I believe you are about to see the faith you've placed in us be acknowledged in a positive fashion."

DYOR, get a bag and hodl

Your welcome.

$IUGNF / $IMU (ASX) Cancer immunotherapy treatment

We have received ethics approval from the external independent Human Research Ethics Committee (HREC) in Australia and Independent Review Boards (IRB'S) in the USA, in addition to the coveted US FDA Investigational New Drug (IND) approval to begin Phase 1 clinical trails of our immunotherapy drug, PD1-Vaxx. Read the entire newsletter with links on site.

From the Chairman Paul Hopper in Dec newsletter: "I believe you are about to see the faith you've placed in us be acknowledged in a positive fashion."

DYOR

"I believe you are about to see the faith you've placed in us be acknowledged in a positive fashion," Paul Hopper, Chairman.

See attached link to December newsletter

chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5fc72d1f3ac9c763f4d28c70/1606888739244/IMU4260_Newsletter_OctHol+2020_Web.pdf

Updated Bell Potter price target

chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5fc82f15f97c193540e5fed1/1606954779040/IMU20201203.pdf

GREAT NEWS! Wow, this is amazing. Can't believe there isn't more action here.

https://www.imugene.com/announcements


IMUGENE LIMITEDACN 009 179 551WWW.IMUGENE.COMinfo@imugene.comASX Announcement Imugene’s HER-Vaxx shows positive Overall Survival with Hazard Ratio of 0.418in Ongoing Randomized Phase 2 Trial in AdvancedGastric Cancer.

•Interim analysis in the randomized Phase 2 showed statisticallysignificant overall survival Hazard Ratio (HR) of 0.418 (80% 2-sided CI: 0.186, 0.942); HER-Vaxx showed a reduced risk of death of 58.2% in the HER-Vaxxplus chemotherapy group as compared to chemotherapy alone.•Themedianoverall survival (OS) for patients receiving HER-Vaxx plus chemotherapy was 14.2 months, compared to 8.8months in patients treated with chemotherapy alone.•The Phase 2 data represent a clinical proof-of-concept signal for HER-Vaxx when added to chemotherapy and indicate that B-cell activating immunotherapyvaccines can induce clinically active antibody responses.•The Independent Data Monitoring Committee (IDMC) confirms a favourable survival outcomewith no added toxicityforHER-Vaxx combinedwith SOC chemotherapyover chemotherapy alone and advises to lower the number of patients required for study completion. Sydney, Australia, 23November2020:Imugene Limited(ASX:IMU),a clinical stage immuno-oncology company,is pleased to share positive interim data from its ongoing Phase 2 study of HER-Vaxx in Her-2/Neu overexpressing advanced/metastatic gastric/GEJcancer.HER-Vaxx Phase 2 interim analysis safety and efficacy data were reviewed at the IDMCmeeting.As a result of the review, theIDMC reported no safety concernsand viewed this preliminary data as strongly in favour of a HER-Vaxxsurvival effect. The interim analysis results from this clinical proof-of-concept study,which was designed with a specified 1-sided false positive probability of 0.10,showedtwice as many patients survived on the HER-Vaxx plus SOC chemotherapy treatment arm compared totheSOC chemotherapy control arm. This translated into an overall survival HR of 0.418 (80% 2-sidedCI: 0.186, 0.942) witha statistically significant 1-sided p-value of 0.083. There was no difference in safety eventsbetween the two treatment arms, suggesting that HER-Vaxx does not add toxicity to SOC chemotherapy. The longestHER-Vaxx treated patient remains on therapy and progression-free 16.3 months after dosing. Historical
2IMUGENE LIMITED ACN 009 179 551 data fromthe ToGA Phase 3 study which examined the effect of Herceptin plus chemotherapy versus chemotherapy alone in advancedgastric cancer, had an overall survival HR of 0.74for the intent-to-treat analysis. The study included thesame patient population of HER2 overexpressing patients in the HER-Vaxx Phase 2 study. The IDMC provided guidance that it is scientifically and ethically appropriate to reduce the overall number of patients required to complete the studygiven the strong signal observed in the data. Imugene’s MD & CEO, Mrs Leslie Chong said, “I am delightedto report that we have achieved this significant milestonefor patients with advanced gastric cancer. I am excited that the interim analysis favoured the survival outcome for HER-Vaxx and the IDMC suggested to shorten the study by lowering the number of patients. This data represents a clinical proof-of-concept for HER-Vaxx and supports our B-cell activating immunotherapy platform. I look forward to updating the market as the data matures.” Imugene’s HER-Vaxxis a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies, in Phase Iand now Phase 2 studiesto stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.The Phase 2 HER-Vaxx study is designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer overexpressing the HER-2 protein. The study is randomised into two arms of either HER-Vaxx plus standard-of-care chemotherapy or standard-of-care chemotherapyalone. The primary endpoint is overall survival and secondary endpoint will be progression-free survival. Safety, tolerability and immune response will also be measured.The Phase 2 trial is being conducted at multiple sites across Eastern Europe and India where clinicians have difficulty accessing approved antibody treatments such as Herceptinâand Perjetaâmarketed by Swiss multinational Roche Holding AG. There is also a high prevalence of gastric cancer in the countries selected. Full study details can also be found on clinicaltrials.gov under study ID: NCT02795988

Interesting point on IMU hotcopper (go to hotcopper for further review:)

https://hotcopper.com.au/threads/why-imu-is-a-multi-multi-bagger.5431324/

I have mentioned in previous posts i don’t believe the ASX market has attributed any value whatsoever to CF33 at current prices, or even at 10-12c for that matter.
We have a super impressive pipeline . “Game changing, paradigm shift, potentially disruptive to market leading blockbuster monoclonal antibodies and chemotherapy” , are the things being said.
A sum of the parts valuation today by any metric simply can not reasonably equal 3.5 for what has already been demonstrated to work!

HerVax + PD1 Vax+ CF33+ Mimitopes = US$ 100million! Seriously?

With HerVax the original Imugene product already advanced to halfway through Ph2 this is what the market is primarily focusing on and attributing current value.
How about attributing some realistic value for CF33.
Just look closely at the Oncolytic Virus landscape.
As four starting points ;

got same but it redirected my browser, just viewing landing page for a stock. Happened three times already. Using desktop and chrome

Short video

FDA Grants IDE Approval of Pivotal Study Evaluating AVITA Medical's RECELL System

Business Wire
10.28.19

AVITA Medical has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to conduct a pivotal trial evaluating the safety and effectiveness of the RECELL Autologous Cell Harvesting Device (RECELL System) in combination with meshed autografting for the treatment of acute full-thickness skin defects, such as degloving (a type of injury where the skin is ripped from the underlying tissue), crush wounds (a break in the external surface of the body), abrasions, lacerations, and surgical wounds.

“FDA approval of our IDE for a soft tissue reconstruction pivotal clinical trial is an important next step in expanding the potential indications of our RECELL System technology platform. We are pleased with the interest expressed by the clinical community in participating in this study and we look forward to working with physicians and their patients upon study commencement,” said Dr. Michael Perry, CEO of AVITA Medical. “Many burn specialists who have experience treating burn patients with the RECELL System also treat patients with trauma injuries in their clinics. The treatment protocols for burns and trauma are well-aligned and as such, we anticipate a positive transfer of clinical experience to benefit this patient population during the clinical trial.”

Skin grafting is the standard of care for soft tissue reconstruction, including post-trauma and post-surgical skin reconstruction. Skin grafting requires the harvesting of donor skin, resulting in an additional wound to the patient. Significant pain, delayed healing, risk of infection, the need for multiple procedures, discoloration and scarring are associated with donor site wounds. While skin grafting is commonly associated with burn treatment, in 2017 approximately 80 percent of acute wounds that required skin grafting were non-burn related injuries accounting for more than 200,000 procedures in the U.S.i

“Based on the safety and effectiveness of the RECELL System in treating burn wounds, we believe our technology is ideally positioned to be evaluated as a treatment to heal trauma- and surgery-related wounds,” said Andy Quick, chief technology officer of AVITA Medical. “With a clear opportunity to improve the standard-of-care, we look forward to sharing results upon completion of this pivotal trial.”

AVITA Medical will initiate a prospective, multi-center, randomized controlled study to compare the clinical performance of conventional skin grafting with and without the use of the RECELL System on acute non-burn full-thickness skin defects. Each patient will have a control wound treated with conventional skin grafting and a wound treated with expanded skin grafting in combination with the RECELL System. The study’s two primary effectiveness endpoints are:

Incidence of healing by eight weeks post treatment
Donor skin sparing, evaluated by comparing the ratios of donor skin required to treat the wounds

Healing will be evaluated by a qualified clinician blinded to the treatment allocation. Additional long-term safety and effectiveness data collected over the course of the 52-week study will include blinded evaluation of scar outcomes and patient treatment preference.

The pivotal studies leading to the RECELL System’s FDA premarket approval (PMA) for the treatment of acute thermal burns demonstrated that the RECELL System treated burns using 97.5ii percent less donor skin when used alone in second-degree burns, and 32 percent less donor skin when used with autograft for third-degree burns.iii Despite the statistically significant reduction in donor skin required to treat burn patients with the RECELL System, burn wounds treated with the RECELL System achieved healing comparable to the burn wounds treated with standard of care. Donor site outcomes from the clinical trial for second-degree burns also revealed a statistically significant reduction in patient-reported pain, increased patient satisfaction and improved scar outcomes.ii

AVITA Medical is a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a patient’s own skin. With its technology platform, AVITA Medical is advancing the standard of care for burn patients and is poised to address unmet medical needs across a range of dermatological indications, including vitiligo, wounds, and aesthetic rejuvenation. The company’s patented and proprietary collection and application technology prepares a REGENERATIVE EPIDERMAL SUSPENSION (RES) comprising the patient’s skin cells necessary to regenerate a natural healthy epidermis that can then be sprayed onto the areas of the patient’s skin requiring treatment.

AVITA Medical’s first U.S. product, the RECELL System, was approved by the FDA in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point-of-care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. In international markets the company's products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, acute wounds, scars and vitiligo. The RECELL System is TGA-registered in Australia, CFDA-cleared in China, and has CE-mark approval in Europe.

References
i 2017 Procedural Data. © 2019 DR/Decision Resources, LLC
ii Holmes JH, Molnar JA, Carter JE, et al. A comparative study of the RECELL® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. J Burn Care Res. 2018
iii Holmes JH, Molnar JA, Shupp JW, et al. Demonstration of the safety and effectiveness of the RECELL System combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries. Burns. 2019;45:772-782.

Closing of $25 million Convertible Debenture Unit Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") (TSXV: EMH; OTCQX: EMHTF) announces that it has closed its prospectus offering (the "Offering") to certain Canadian institutional accredited investors announced on August 28, 2019. Pursuant to the Offering, the Company issued 2,500 secured convertible debenture units (each, a "Convertible Debenture Unit") at a price of $10,000 per Convertible Debenture Unit (the "Issue Price") for gross proceeds of $25,000,000.

Each Convertible Debenture Unit is comprised of one 5.0% secured convertible debenture of the Company in the principal amount of $10,000 (each, a "Convertible Debenture") and 5,000 common share purchases warrants of the Company (each, a "Warrant"). The Convertible Debentures have a maturity date of 24 months from the date hereof (the "Maturity Date") and bear interest (at the option of the Company payable in cash or, pursuant to TSXV rules and subject to certain limitations on a holder’s ownership levels, in common shares of the Company ("Common Shares")) from the date hereof at 5.0% per annum, accrued and payable semi-annually on June 30th and December 31st of each year. The Convertible Debentures include certain covenants relating to the business of the Company.

Subject to certain limitations on a holder’s ownership levels, the Convertible Debentures are convertible, subject to certain restrictions and at the option of the holder, into Common Shares at any time prior to the close of business on the last business day immediately preceding the Maturity Date. The Convertible Debentures have a conversion price of $2.00 per Common Share (the "Conversion Price"). If, at any time prior to the Maturity Date, the volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the "TSXV") is greater than $3.50 for 10 consecutive trading days, the Company may force the conversion of the principal amount of the then outstanding principal amount owing pursuant to the Convertible Debentures at the Conversion Price provided the Company gives 30 days' notice of such conversion to the holder.

Subject to certain limitations on a holder’s ownership levels, each Warrant is exercisable to purchase one Common Share at an exercise price of $2.00 per share for a period of 24 months from the date hereof. If, at any time prior to the expiry date of the Warrants, the volume weighted average trading price of the Common Shares on the TSXV is greater than $3.50 for 10 consecutive trading days, the Company may deliver a notice to the holder of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice.

The Company has used a portion of the net proceeds of the Offering to repay the outstanding loan to Emerald Health Sciences Inc. and intends to use the remainder for working capital.

The Convertible Debenture Units were offered by way of a shelf prospectus supplement dated August 30, 2019 filed in all of the provinces of Canada pursuant to National Instrument 44-101 Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions.

This press release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is licensed and fully planted in the first of its two 1.1 million square foot greenhouses. The capacity of each greenhouse is estimated to exceed 75,000 kg of cannabis annually. Emerald's Verdélite operation in Québec is completing the build-out of its 88,000 square foot indoor cultivation facility and is scaling up production. Emerald has contracted for approximately 1,200 acres of hemp in 2019 to 2022 with the objective of extracting low-cost cannabidiol. Emerald has secured exclusive strategic partnerships for large scale extraction and softgel encapsulation, as well as for proprietary technology to enhance cannabinoid bioavailability. Its team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers.

Emerald is part of the Emerald Health Group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products aimed at providing wellness and medical benefits by interacting with the human body's endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:

Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. # 5

Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Yup, got a call and spent quite a few mins talking. Gonna listen to conf call.

Any idea if they plan to get off pink sheets to QB?

VANC Contracts with Lampyon to Extend its Corozon Educational and Ecommerce Platform with Medical Cannabis Education and New Sales Capabilities

https://finance.yahoo.com/news/philippe-ugnat-llb-joins-vanc-003239638.html

Looking good in here.

http://nasdaqnewsreports.blogspot.de/2018/05/buying-undervalued-weed-and-pharma.html

$NMUS Nemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics

I guess they have to sell enough shares to pay for buying the coins, and they're doing it here.

Emerald Health bought into Vanc? Distribution channel? Wow. Load and hold. EMHTF?

Insider Roster
Individual or Entity Most Recent Transaction Date Shares Owned as of Transaction Date

EMERALD HEALTH THERAPEUTICS, INC.
10% Security Holder of Issuer
Opening Balance-Initial SEDI Report

Nov 27, 2017
1,666,667

HALL (DAVID M.)
Director of Issuer
Acquisition or disposition under a prospectus exemption

Jun 25, 2017
333,333

RAI (BOB SUKHWINDER S)
Director of Issuer
Acquisition or disposition under a prospectus exemption

Aug 2, 2017
333,334

*Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.

VANC Pharmaceuticals Plans to Launch INSTI HIV Test with United Pharma Group on World AIDS Day https://buff.ly/2kwCsXk

Check out partners of United Pharma Group partners. Mylan, Novartis, etc.
http://www.unitedpharmagroup.ca/our-partner/

News out this morning
VANCOUVER, British Columbia, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Tinkerine Studios Ltd. (Tinkerine or the Company) (TSX-V:TTD) (FSE:WB6B) and (OTC:TKSTF) is pleased to announce the launch of two (2) new additions to Tinkerines filament line. The two products, Ht Filament and Limited Series Filament Initiative will bring more choices to customers and greatly complements the Companys existing product line. Ht Filament is our specially formulated high temperature resistant filament that can handle up to 90 degrees Celsius in air. With Ht, we change the way we look at the need for ABS while maintaining the ease of use, safety, reliability of PLA, and the strength of what we want from ABS, says Eugene Suyu, President and CEO of Tinkerine. Limited Series Filament Initiative takes a new approach on how we get to understand what our customers are looking for. The color choices are not selected by Tinkerine, but instead driven by those that are leading the industry forward and produced in a limited production run. With the introduction of the two new additions of our filament line of products, we look to change the way the industry looks at filament. The depth of how we get to understand our customers will ultimately be how we bring value to the shareholders as well as our customers, added Suyu. The filament can now be purchased on the Tinkerine Website at www.tinkerine.com. ABOUT TINKERINE STUDIOS LTD. Tinkerine Studios designs and manufactures user-friendly award winning 3D printers and software, with a focus on STEAM based educational content and online training tools. Tinkerine also manufactures its own line of high purity filament for 3D printers. Tinkerine and Ditto are registered trademarks of Tinkerine Studios Ltd., all rights reserved. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Anyone see this? This guy worked with Apple in the past. Great news!

http://tinkerine.com/wp-content/uploads/2016/01/ttd06242016final.pdf

Tinkerine Annual General Meeting Results and Appointments to
Board of Directors
Vancouver, B.C. – June 24, 2016 ­­ Tinkerine Studios Ltd. (“Tinkerine” or the “Company”)
(TSXV: TTD, FSE: WKN WB6B and OTC: TKSTF) i?s pleased to ?announce results from the Annual
General Meeting (“AGM”) held on June 23, 2016 in Vancouver, British Columbia. In addition to the
existing directors, the Company has added Mr. Bob Longo and Mr. Justin Sy to the Board of Directors.
New Additions to the Board of Directors
Mr. Bob Longo
Mr. Longo is current Chief Executive Officer (“CEO”) and President of Knowmatters, Inc., a US­based
education firm focused on cognitive learning and artificial intelligence. Mr. Longo has specific expertise
in CEO strategic and operational support, sales, marketing, executive general management and
strategic planning.
Mr. Longo previously held senior positions with Apple Inc., Carnegie Learning, Studywiz, SchoolOne
and NeXT Inc. During his tenure at Apple and NeXT his duties included responsibilities in both the
K­12 and Higher Education markets. Mr. Longo worked with Steve Jobs three times. He headed up
the K­12 market and later was President of Apple’s PowerSchool Division, leading it to three
consecutive years of increased growth in revenue, profit and market share. This included recognition
as the Software Information Industry Association’s (SIIA) CODIE winner each year, for Best Software
in its category. Mr. Longo was President, CEO and Vice Chairman at Carnegie Learning, a leading
adaptive math software developer and publisher. He successfully launched the Carnegie
Mellon’s spin­out penetrating 40% of the largest 100 US School Districts in its first 36 months, while
tripling revenue each year. At Carnegie Learning he was recognized as an Ernst &
Young Software Entrepreneur of the Year and was twice invited to present to the US governors at their
Education Technology Summit. At both PowerSchool and Carnegie Learning his teams secured 99%
Customer Retention Rates. Mr. Longo was Executive Vice President at Studywiz, and was responsible
for the expansion of sales to K­12 schools in North America and for developing strategic relationships
with major industry partners including Apple, Google and Microsoft. Mr. Longo was CEO of
SchoolOne, an education technology company that developed and marketed web­based, enterprise,
information software solutions to the K­12 market, their clients included all of the Catholic Schools in
the Silicon Valley.
Mr. Justin Sy, Interim Chief Financial Officer (“CFO”)
Mr. Sy is one of the founders of Tinkerine and has been directly involved in the development of
software for the DittoPro 3D Printer. Mr. Sy has participated in a number of 3D printing related
competitions and is the founder of Puppeteer, a 3D imaging software used to control hand motions via
a connected glove. Mr. Sy received a runner­up award for this project in the BCNET Digital Media
Challlenge. Mr. Sy also holds a B.Sc from Simon Fraser University. Mr. Sy was appointed interim CFO
on February 24, 2016.

Great time to get in now, 800% growth in six months. Demand for generics is high, and their otc products have great margins!

Tinkerine had a private placement of 500K http://investingnews.com/daily/tech-investing/3d-printing-investing/tinkerine-studios-announces-500000-private-placement/

Affinor Growers Receives Purchase Order from Major Grower and Distributor to install State of the Art Vertical Growing System in Michigan USA

http://www.affinorgrowers.com/en/investors/news-releases/affinor-growers-receives-purchase-order-from-major-grower-and-distributor-to-install-state-of-the-art-vertical-growing-system-in-michigan-usa

Affinor Growers Arranges a Private Placement of Up to $500,000
MONTREAL, CANADA--(Marketwired - Aug 24, 2015) - Affinor Growers (CSE:AFI)(FRANKFURT:1AF)(OTCQB:RSSFF) ("Affinor" or the "Corporation), a diversified agriculture and biotechnology company with proprietary vertical farming systems, announces a non-brokered private placement of up to $500,000 at a price of five cents per unit.

Under the terms, each unit is comprised of one common share at five cents and one whole share purchase warrant of the Corporation. The common share purchase warrant has a term of one year, exercisable at fifteen cents per share. The net proceeds of this private placement will be used for working capital. A cash commission equal to 7 per cent of the gross proceeds of the private placement might be payable. The closing of the private placement is expected to be on or about August 28, 2015.

About Affinor Growers Inc.

Affinor Growers is a diversified publicly traded company on the Canadian Securities Exchange under the symbol ("AFI"). Affinor is focused on growing high quality crops such as romaine lettuce, spinach, strawberries. Affinor is committed to becoming a pre-eminent grower, using exclusive vertical farming techniques.
On Behalf of the Board of Directors

AFFINOR GROWERS INC.

Sebastien Plouffe, President & CEO

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

FORWARD LOOKING INFORMATION

This News Release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com. This News Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Affinor Growers Inc.
Amanda Weber, Corporate Consultant
(604) 512-3230
Amanda@affinorgrowers.com
www.affinorgrowers.com

Update from Nick:

Tinkerine Studios adds leading Asian 3D printing distributor DTSL Group servicing Hong Kong and Macau markets


http://www.prnewswire.com/news-releases/tinkerine-studios-adds-leading-asian-3d-printing-distributor-dtsl-group-servicing-hong-kong-and-macau-markets-500902601.html

HIGHLIGHTS:

Hong Kong-based DTSL targets educators, students, designers, architects, and hobbyists in the Greater China market.
DTSL provides an all in one 3D printing bundle offering consisting of Tinkerine's Ditto™Pro 3D printer and software, high purity filament, and Tinkerine U educational content.
DTSL has supplied and supported in excess of 100 schools and universities in the Hong Kong market over the past 3 years with 3D printing solutions.
VANCOUVER, April 22, 2015 /CNW/ - Tinkerine™ Studios Ltd. (TSXV: TTD, FSE: WKN WB6B and OTC: TKSTF), Canada's leading manufacturer of the award winning Ditto™Pro 3D desktop printer and 3D printing educational content, is pleased to announce it has commenced shipment to DTSL Group ("DTSL") Hong Kong's leading 3D printing distributor and solutions provider.

With DTSL signing on with Tinkerine as a dealer, DTSL will continue to increase its position as one of the leading 3D printing solution providers to schools, designers, architects and hobbyists by offering Tinkerine's Ditto™Pro 3D printer and software, consumables, and online training support through Tinkerine U.

Jack Wu, Business Director at DTSL commented, "DTSL has been promoting 3D printing in education sectors within the Greater China region for three years now. Based on our experience deploying 3D technology in more than 100 schools and universities, merely having a 3D printer is not enough to ensure educators and their students apply 3D printing technology effectively in learning and teaching. Tinkerine U provides a global education platform that will greatly assist in DTSL extending its reach."

Tinkerine's Channel Service Manager, Vivian Chu added "Hong Kong is an important market for us and we continue to add new channel partners every month. Teaming up with DTSL gives us a stronger foothold in the Hong Kong education market and they share our vision of how we see 3D printing technologies supporting a whole new generation of design thinkers."

ABOUT DTSL

DTSL is a leading 3D printing solution provider in Hong Kong who provides a full suite of 3D printing and scanning solutions for designers, architects, students and hobbyists to enable them to see, hold and test their ideas in real space. With a variety of products and solutions ranging from entry-level to professional grade, end-users can experience the latest cutting-edge technologies and unleash their unlimited creativity. DTSL also offer professional and tailor-made technical consultancy, hassle-free post-sales support and 3D printing service to various industries, including higher education, K12, design and manufacturing.

http://www.dtsl.asia/

ABOUT TINKERINE STUDIOS LTD.

Tinkerine develops, manufactures, and sells desktop 3D printers, content, and software for the consumer and education markets, the fastest growing segments of 3D printing. Current products include the award winning Ditto™ Pro, Ditto+, and Litto 3D printers, all acclaimed for their high performance and affordability. Tinkerine's 3D printers work seamlessly with the Company's integrated 3D software to make printing intuitive and accessible to anyone. Tinkerine backs its products and services with Tinkerine U, the Company's 3D educational content and online training platform. With a focus on education, Tinkerine continues to provide 3D printing solutions into the US$86 billion educational technology and US$122 billion online training markets.

CAUTIONARY NOTES

Certain information in this news release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Tinkerine assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Tinkerine. Additional information identifying risks and uncertainties is contained in Tinkerine's filings with the Canadian securities regulators available at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Tinkerine Studios Ltd.

Zacks gives "STRONG BUY". PT of $15.88. Great Entry here

Tinkerine enters into agreement for new markets with 3D printing distributor PRECISE Group launching sales in 100 locations http://www.otcmarkets.com/stock/TKSTF/news

$NUVPF Vanc gains B.C. gov't approval for 14 drug generics. This is the real deal, insider buying and volume on Canadian side gaining ground. Just a matter of time here. Do you realize how many people are on these drugs? Wheww!!


http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aNPH-2253249&symbol=NPH

Vanc gains B.C. gov't approval for 14 drug generics

2015-02-24 08:09 ET - News Release



Mr. Arun Nayyar reports

VANC PHARMACEUTICALS ANNOUNCES LOW COST ALTERNATIVE APPROVAL OF 14 PRODUCTS FROM BRITISH COLUMBIA MINISTRY OF HEALTH

Vanc Pharmaceuticals Inc. has received confirmation from the B.C. Ministry of Health approving 14 of the company's generic molecules under the Low Cost Alternative program. The approval of these molecules makes them eligible for listing on British Columbia's provincial formulary and for reimbursement through Pharmacare. Pharmacare is the province's coverage plan that assists residents with the cost of eligible prescription drugs and certain medical supplies.

"We are excited to have received LOA approval from the B.C. Ministry of Health as it signifies an important milestone in our evolution as a company -- we can now provide residents of B.C. with safety, quality and affordability when it comes to these 14 molecules," said Arun Nayyar, chief executive officer of Vanc. "We will continue to work with the Ministry of Health to gain approval of additional molecules during Q1 2015."

14 APPROVED PRODUCTS
Brand
Molecule name Presentations reference

VAN-Rizatriptan 5 mg tab Maxalt
VAN-Amlodipine 5 mg and 10 mg tab Norvasc
VAN-Losartan 25 mg, 50 mg and 100 mg tab Cozaar
VAN-Losartan-HCTZ 50+12.5 mg and 100+25 mg tab Hyzaar
VAN-Levetiracetam 250 mg, 500 mg and 750 mg tab Keppra
VAN-Gabapentin tab 600 mg and 800 mg tab Neurontin
VAN-Omeperazole 20 mg DR tab Losec
VAN-Finasteride 5 mg tab Proscar
VAN-Olanzapine 2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg Zyprexa
tab
VAN-Sertraline cap 25 mg, 50 mg and 100 mg cap Zoloft
VAN-Pantoprazole 40 mg tab Pantoloc
VAN-Gabapentin cap 100 mg, 300 mg and 400 mg cap Neurontin
VAN-Ciprofloxacin 250 mg, 500 mg and 750 mg tab Cipro
VAN-Sildenafil 25 mg, 50 mg and 100 mg tab Viagra



About Low Cost Alternative program

The B.C. Ministry of Health established the Low Cost Alternative program under the Drug Price Regulation to ensure the best value is obtained for expenditures on multisource drugs. The program works by limiting Pharmacare reimbursements for drug products subject to an LCA price.

We seek Safe Harbor.

$NUVPF Vanc gains B.C. gov't approval for 14 drug generics. This is the real deal, insider buying and volume on Canadian side gaining ground. Just a matter of time here. Do you realize how many people are on these drugs? Wheww!!


http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aNPH-2253249&symbol=NPH

Vanc gains B.C. gov't approval for 14 drug generics

2015-02-24 08:09 ET - News Release



Mr. Arun Nayyar reports

VANC PHARMACEUTICALS ANNOUNCES LOW COST ALTERNATIVE APPROVAL OF 14 PRODUCTS FROM BRITISH COLUMBIA MINISTRY OF HEALTH

Vanc Pharmaceuticals Inc. has received confirmation from the B.C. Ministry of Health approving 14 of the company's generic molecules under the Low Cost Alternative program. The approval of these molecules makes them eligible for listing on British Columbia's provincial formulary and for reimbursement through Pharmacare. Pharmacare is the province's coverage plan that assists residents with the cost of eligible prescription drugs and certain medical supplies.

"We are excited to have received LOA approval from the B.C. Ministry of Health as it signifies an important milestone in our evolution as a company -- we can now provide residents of B.C. with safety, quality and affordability when it comes to these 14 molecules," said Arun Nayyar, chief executive officer of Vanc. "We will continue to work with the Ministry of Health to gain approval of additional molecules during Q1 2015."

14 APPROVED PRODUCTS
Brand
Molecule name Presentations reference

VAN-Rizatriptan 5 mg tab Maxalt
VAN-Amlodipine 5 mg and 10 mg tab Norvasc
VAN-Losartan 25 mg, 50 mg and 100 mg tab Cozaar
VAN-Losartan-HCTZ 50+12.5 mg and 100+25 mg tab Hyzaar
VAN-Levetiracetam 250 mg, 500 mg and 750 mg tab Keppra
VAN-Gabapentin tab 600 mg and 800 mg tab Neurontin
VAN-Omeperazole 20 mg DR tab Losec
VAN-Finasteride 5 mg tab Proscar
VAN-Olanzapine 2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg Zyprexa
tab
VAN-Sertraline cap 25 mg, 50 mg and 100 mg cap Zoloft
VAN-Pantoprazole 40 mg tab Pantoloc
VAN-Gabapentin cap 100 mg, 300 mg and 400 mg cap Neurontin
VAN-Ciprofloxacin 250 mg, 500 mg and 750 mg tab Cipro
VAN-Sildenafil 25 mg, 50 mg and 100 mg tab Viagra



About Low Cost Alternative program

The B.C. Ministry of Health established the Low Cost Alternative program under the Drug Price Regulation to ensure the best value is obtained for expenditures on multisource drugs. The program works by limiting Pharmacare reimbursements for drug products subject to an LCA price.

We seek Safe Harbor.

More great news, Tinkerine has partnered with FutureBooks yearbooks...check it out!


http://finance.yahoo.com/news/tinkerine-partners-futurebook-yearbooks-north-140000374.html;_ylt=AwrBT80YSetUrj0AXm9XNyoA;_ylu=X3oDMTByMjB0aG5zBGNvbG8DYmYxBHBvcwMxBHZ0aWQDBHNlYwNzYw--

Tinkerine Partners with FutureBook Yearbooks, North America's Fastest Growing Yearbook Printing and Publishing Company
CNW Group Tinkerine Studios Ltd.
1 hour ago
????
FutureBook Yearbooks will bundle Tinkerine's award-winning Ditto™Pro 3D printer as part of its North American educational institutional offerings

VANCOUVER , Feb. 23, 2015 /CNW/ - Tinkerine™ Studios Ltd. (TSXV: TTD and OTC Pink: TKSTF), Canada's leading manufacturer of desktop 3D printers and 3D printing educational content, today announced a partnership with FutureBook Yearbooks, North America's fastest growing yearbook printing and publishing company.

Tinkerine's Ditto™Pro will become a feature item in Futurebook Yearbook's Awards Program offering to educational institutions. The Awards Program gives educational institutions an allowance to purchase classroom technology, which will now include 3D printers.

FutureBook Yearbooks CEO Reid Felske stated, "FutureBook Yearbooks believes in inspiring, educating, and empowering students. By partnering with Tinkerine, our mission grows. We are thrilled about this relationship and know that together, our customers will experience boundless creativity, innovation, and excitement."

Tinkerine CEO Eugene Suyu added, "FutureBook Yearbooks is a value added partner that has a significant and expanding footprint in the North American education market. Their focus is highly relevant and complements our vision of educating and training teachers and students about the use and benefits of 3D printing technology".

Tinkerine is committed to partnering with best in class companies like FutureBook Yearbooks that provide high quality, innovative products to the education market backed by strong customer service.

ABOUT FUTUREBOOK

FutureBook Yearbooks is the progressive leader in the school yearbook market, offering the industry's highest quality yearbooks at the industry's best price with outstanding service and delivery flexibility. Innovative and exclusive products such as the ProofBook, MovieBook, GradBox, and Awards provide richer and more meaningful experiences for yearbook recipients and greater customer satisfaction for the teachers and students that plan them.

ABOUT TINKERINE STUDIOS LTD.

Tinkerine develops, manufactures, and sells desktop 3D printers, content, and software for the consumer and education markets, the fastest growing segments of 3D printing. Current products include the award winning Ditto™Pro, Ditto+, and Litto 3D printers, all acclaimed for their high performance and affordability. Tinkerine's 3D printers work seamlessly with the Company's integrated 3D software to make printing intuitive and accessible to anyone. Tinkerine backs its products and services with Tinkerine U, the Company's 3D educational content and training platform. With a focus on education, Tinkerine continues to position itself as the emerging leader in the 3D printer industry.

Tinkerine shares are listed on the TSXV, under the symbol TTD.V and TKSTF on the OTCPink.

CAUTIONARY NOTES

Certain information in this news release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Tinkerine assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Tinkerine. Additional information identifying risks and uncertainties is contained in Tinkerine's filings with the Canadian securities regulators available at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Tinkerine Studios Ltd.

View photo
.
Contact:
FutureBook Yearbooks: Dana Felske, 604-662-7687, dana@futurebookyearbooks.com; Investor Relations: Sean Peasgood, 416.565.2805, Sean@SophicCapital.com; Tinkerine Studios: John Ross, 778.322.0445, JohnR@Tinkerine.com

OMG! Excellent news. Low floater! Looking good.

Tinerkerine U, education for 3d printing now has an app.

Tinkerine iOS iPad App Brings 3D Printing into the Classroom


http://finance.yahoo.com/news/tinkerine-ios-ipad-app-brings-113000030.html;_ylt=AwrBT83JVuNUpHcAi.lXNyoA;_ylu=X3oDMTEzcDJlMzU2BGNvbG8DYmYxBHBvcwMyBHZ0aWQDU01FNjUyXzEEc2VjA3Nj

WNTR, you wanna play, you gotta pay! It may be wntr, but she's hot, buybacks baby!

Message from the CEO:

http://www.tinkerine.com/investor/2015/TinkerineCEOLetter12.pdf

Check out the video, and the lessons from TinkerineU are there now....

http://www.tinkerineu.com/welcome.php

Tinkerine Signs Canadian 3D Printer Dealer Voxel Factory, Enters Quebec and Eastern Seaboard Market


Tic toc, tic toc, don't miss the clock!


https://research.tdwaterhouse.ca/research/public/Stocks/NewsArticle/ca/TTD?documentKey=100-318c1299-1

Voxel Factory now selling Tinkerine 3D printers. https://www.facebook.com/VoxelFactory/posts/875570849128070

More good news! Tinkerine's DittoPro 3D Printer Awarded For Overall Performance By MAKE Magazine

http://www.prnewswire.com/news-releases/tinkerines-dittopro-3d-printer-awarded-for-overall-performance-by-make-magazine-282449511.html

Two Year Old Brand Delivers High Quality Customer Experience As It Competes Against The Industry's Biggest Players And Latest Upstarts To Bring 3D Printing To The Masses

VANCOUVER, Nov. 12, 2014 /CNW/ - Tinkerine™ Studios Ltd. (TSXV: TTD and OTC Pink: TKSTF) Canada's leading manufacturer and distributor of 3D printers, is pleased to announce that its Ditto™Pro printer was recently featured in MAKE Magazine's Annual 2015 Ultimate Guide to 3D Printing. The magazine tested 26 of the top desktop 3D printers for overall performance, notable print quality, and price.

The review highlighted the DittoPro's overall high performance during the extensive testing; and placed it consistently near the top in terms of reliability, software integration, upgradeability, number of features, price, and print quality (dimensional accuracy, surface finish, overhang capabilities, and more).

The magazine editors were quoted in their evaluation: "The DittoPro is a great-looking machine with print performance to match. It scored as well as some of the best printers we tested, while far less expensive than most of them... we believe that the combination of good design and easy to use software would make it ideal for new users."

Tinkerine CEO, Eugene Suyu commented "We are honoured to win MAKE Magazine's praise for a second year in a row. We know that when one factors in design, ease of use and overall performance, with price and customer experience, that the DittoPro remains one of the best value printers in the market today and is the perfect choice for schools and general users. We've built our business on providing great value and believe this will drive significant consumer adoption."

About Tinkerine

Tinkerine develops, manufactures, distributes, and sells 3D printers, software and materials for the consumer and education markets, the fastest growing segments of 3D printing. Current products include the recently released Ditto Pro, the award-winning Ditto+ and Litto 3D printers, all acclaimed for their high performance and affordability. Tinkerine's 3D printers work seamlessly with its integrated 3D software to make printing intuitive and accessible to anyone. With a major focus on education, Tinkerine continues to position itself as one of the emerging leaders in the 3D printer market both in North America and abroad.

Tinkerine shares are listed on the TSXV, under the symbol TTD.V and TKSTF on the OTCPink.

About MAKER MEDIA

Maker Media is a global platform for connecting makers with each other, with products and services, and with our partners. Through media, events and ecommerce, Maker Media serves a growing community of makers who bring a DIY mindset to technology. Whether as hobbyists or professionals, makers are creative, resourceful and curious, developing projects that demonstrate how they can interact with the world around them. The launch of Make: Magazine in 2005, followed by Maker Faire in 2006, jumpstarted a worldwide Maker Movement, which is transforming innovation, culture and education. Co-located in Sebastopol and Oakland, CA, Maker Media is the publisher of Make: Magazine and the producer of Maker Faire. The Make: brand caters to a universe of more than 25 million makers collectively across its Make: magazine, makezine.com, Maker Faires, and Maker Shed properties.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Tinkerine and Ditto are registered trademarks of Tinkerine Studios Ltd., all rights reserved.

Certain statements contained in this press release may constitute forward-looking statements and Tinkerine cautions that actual results may differ materially from those made in the forward-looking statements.

SOURCE Tinkerine Studios Ltd.



RELATED LINKS
www.tinkerine.com

nice video, keeping us updated, another video on the way... Great news. I like the chart, macd curling up, rsi rising to power zone. Get your shares now before penny break!

volume first, then price. Nice video.